logo-loader
RNS
Genus PLC

Board Change: Non-Executive Director Appointment

RNS Number : 5566D
Genus PLC
18 November 2026
 

18 November 2026

Genus plc

(“Genus” or the “Group”)

Board Change: Non-Executive Director Appointment

 

Genus (LSE: GNS), a leading global animal genetics company, is pleased to announce the appointment of Sharmila Nebhrajani to the Board as a Non-Executive Director, with effect from 1 January 2027.  

Ms Nebhrajani is a Chartered Accountant with extensive experience in public sector, commercial, government and non-profit organisations across a wide range of sectors, having worked in senior roles in public health and medical research, working with government, medical charities and pharmaceutical industry partners, and latterly in government, convening international policy dialogue with governments, multi-lateral agencies, NGOs, senior policy makers and academics, on key global policy issues. Her appointment follows an extensive search process using an external search agency.

Ms Nebhrajani has a MA in Physiological Sciences from Oxford University and is currently a non-executive director and remuneration committee chair of Severn Trent plc[1], non-executive director and remuneration committee chair of ITV plc, senior independent director and audit committee chair of Halma plc, non-executive director of Essentra plc and Chair of the National Institute for Health and Care Excellence. She was previously a non-executive director of Coutts & Co.  

Commenting on the appointment, Iain Ferguson, Chair of Genus, said:

“We are delighted to welcome Shar to the Board. Shar is a highly experienced non-executive director and audit committee chair, and brings a broad range of commercial, strategic and scientific experience and knowledge.” 

For further information please contact:

Genus plc Tel: +44 (0)1256 345 970

Iain Ferguson, Chair

Jorgen Kokke, Chief Executive Officer

Tavistock            Tel: +44 (0)20 7920 3150 

 

Nick Dibden / Katie Hopkins 

 

 About Genus

Genus is a world-leading animal genetics company. Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.

Genus's worldwide sales are made in over seventy-five countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chains.

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.

With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

Regulatory Notes

Details of any payments to be made to Sharmila Nebhrajani will be disclosed in full in the Company’s 2027 Directors’ Remuneration Report.  Any such terms will be consistent with the Company's approved Directors’ Remuneration Policy.

 

This announcement is made in accordance with Listing Rule 6.4.6R.   There are no matters to be disclosed in connection with Listing Rule 6.4.8R (2) – (6). The person responsible for making this announcement on behalf of the Group is Lucie Grant (General Counsel and Company Secretary).

 


[1] Sharmila will step down from the Board of Severn Trent plc on 30 November 2026.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAMZMMMKNVGVZM
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

2026 AGM Poll Results

1 day, 4 hours ago

Transaction in Own Shares

3 days, 10 hours ago

Transaction in Own Shares

1 week, 3 days ago

Holding(s) in Company

2 weeks ago

Total Voting Rights

2 weeks, 3 days ago

Transaction in Own Shares

2 weeks, 3 days ago

Transaction in Own Shares

3 weeks, 3 days ago

4 min read